NanoViricides (NNVC+4.0%) has announced that its two COVID-19 clinical drug candidates NV-CoV-2 and NV-CoV-2-R were highly effective in coronavirus-infected animal models based on multiple indicators.

纳米病毒杀菌剂(NNVC+4.0%)近日宣布，基于多个指标，其两种新型冠状病毒临床候选药物NV-CoV-2和NV-CoV-2- r在冠状病毒感染动物模型中有效。

Survival: Compared to treatment with remdesivir, NV-CoV-2 has extended the lifespan by approximately four times more days, while NV-CoV-2-R extended the lifespan by approximately five times more days.

生存期:与瑞德西韦治疗相比，新型冠状病毒2型延长寿命约4天，而新型冠状病毒2- r延长寿命约5天。

Bodyweight: While the Remdesivir group lost ~17% BW (30g/animal) by day 7 and subsequently succumbed to the disease, the NV-CoV-2 group lost about 7% BW (12.5 g/animal) on day 13, and the NV-CoV-2-R group lost ~1.8% BW (3g/animal) at day 13.

体重:瑞德西韦组在第7天损失约17% BW (30g/只)，随后死亡，新冠病毒-2组在第13天损失约7% BW (12.5 g/只)，新冠病毒-2- r组在第13天损失约1.8% BW (3g/只)。

With the support of the data from animal models, the company expects to start human clinical studies and a pre-IND application for the two drug candidates against COVID-19.

在动物模型数据的支持下，该公司预计将启动针对COVID-19的两种候选药物的人类临床研究和ind前申请。

Last week, NanoViricides shares surged in the premarket in response to effectiveness data from cell culture studies for the two antiviral candidates.

上周，纳米病毒杀菌剂的股价在上市前飙升，这是对两种候选抗病毒药物细胞培养研究的有效性数据的回应。